Zentalis Pharmaceuticals, Inc. (ZNTL)
ZNTLNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$1.80
+0.1420 (+8.56%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $164.72m
- P/E
- –
- EPS, last 4 quarters
- $-1.95
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.21 to $6.95
- Average volume
- 1.24m
- Previous close
- $1.66
Analysts
6 coveringBuy4 buy, 2 hold, 0 sell
Targets a year out average $7.50, +316.4% from here
Earnings
next estimate $-0.5800Next report
Sep 2025
+24.5%
Dec 2025
-19.5%
Mar 2026
-2.0%
Jun 2026
-31.1%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$33.73m | -$37.39m | -$37.85m | -$44.39m |
| Net income | -$26.69m | -$35.22m | -$35.35m | -$42.29m |
News
8 latest- Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business UpdatesFintel · 1 hour ago
- Zentalis Reports Interim OS Rates Of 15 Months In Cyclin-E1 PROC Patients Treated With Azenosertib RTTNews · Oct 19, 2026
- Zentalis Highlights Interim Survival Data From DENALI Part 1b Study Of Azenosertib In PROC RTTNews · Oct 19, 2026
- Zentalis Pharma Closes $92.6 Mln Offering Of Shares; Stock Up RTTNews · Aug 18, 2026
- Zentalis Pharma Prices $80.5 Mln Offering Of Shares At $3.50 Per Share; Stock Down RTTNews · Aug 14, 2026
- ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?Zacks · Jul 20, 2026
- Zentalis To Present Part 1 Phase 1b MUIR Trial Results Of Azenosertib At ASCO 2026 RTTNews · May 22, 2026
- Stocks To Watch Today: IDYA, OGN, VRX, REPL... RTTNews · Apr 13, 2026
The company
Zentalis is a clinical oncology innovator developing a treatment approach for ovarian cancer and multiple tumor types. Leveraging therapeutics development and biomarker expertise, Zentalis is advancing monotherapy and combination studies of its investigational first-in-class WEE1 inhibitor, azenosertib. Focused on translating WEE1 science into clinical practice, we aim to equip physicians with a targeted, non-chemo, orally available medicine that enhances treatment experience, choice, and outcomes. Our mission: to unburden cancer patients with more convenience and care.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- zentalis.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.